KR101705011B1 - Ｃｄｃａ１ 에피토프 펩티드 및 이를 포함하는 백신 - Google Patents

Ｃｄｃａ１ 에피토프 펩티드 및 이를 포함하는 백신 Download PDF

Info

Publication number
KR101705011B1
KR101705011B1 KR1020117000740A KR20117000740A KR101705011B1 KR 101705011 B1 KR101705011 B1 KR 101705011B1 KR 1020117000740 A KR1020117000740 A KR 1020117000740A KR 20117000740 A KR20117000740 A KR 20117000740A KR 101705011 B1 KR101705011 B1 KR 101705011B1
Authority
KR
South Korea
Prior art keywords
peptide
antigen
cancer
peptides
cdca1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020117000740A
Other languages
English (en)
Korean (ko)
Other versions
KR20110031314A (ko
Inventor
타쿠야 츠노다
류지 오사와
사치코 요시무라
Original Assignee
온코세라피 사이언스 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 온코세라피 사이언스 가부시키가이샤 filed Critical 온코세라피 사이언스 가부시키가이샤
Publication of KR20110031314A publication Critical patent/KR20110031314A/ko
Application granted granted Critical
Publication of KR101705011B1 publication Critical patent/KR101705011B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020117000740A 2008-06-19 2009-06-18 Ｃｄｃａ１ 에피토프 펩티드 및 이를 포함하는 백신 Active KR101705011B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US7406208P 2008-06-19 2008-06-19
US61/074,062 2008-06-19
US19759908P 2008-10-28 2008-10-28
US61/197,599 2008-10-28
PCT/JP2009/002771 WO2009153992A1 (en) 2008-06-19 2009-06-18 Cdca1 epitope peptides and vaccines containing the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020167027024A Division KR20160119264A (ko) 2008-06-19 2009-06-18 Ｃｄｃａ１ 에피토프 펩티드 및 이를 포함하는 백신

Publications (2)

Publication Number Publication Date
KR20110031314A KR20110031314A (ko) 2011-03-25
KR101705011B1 true KR101705011B1 (ko) 2017-02-23

Family

ID=41433910

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020117000740A Active KR101705011B1 (ko) 2008-06-19 2009-06-18 Ｃｄｃａ１ 에피토프 펩티드 및 이를 포함하는 백신
KR1020167027024A Ceased KR20160119264A (ko) 2008-06-19 2009-06-18 Ｃｄｃａ１ 에피토프 펩티드 및 이를 포함하는 백신

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020167027024A Ceased KR20160119264A (ko) 2008-06-19 2009-06-18 Ｃｄｃａ１ 에피토프 펩티드 및 이를 포함하는 백신

Country Status (16)

Country Link
US (2) US9387238B2 (https=)
EP (1) EP2303912B1 (https=)
JP (1) JP5640262B2 (https=)
KR (2) KR101705011B1 (https=)
CN (1) CN102119171B (https=)
AU (1) AU2009261382B2 (https=)
BR (1) BRPI0914782B1 (https=)
CA (1) CA2728268C (https=)
DK (1) DK2303912T3 (https=)
ES (1) ES2658842T3 (https=)
IL (1) IL209967A (https=)
MX (1) MX2010014044A (https=)
RU (1) RU2502740C2 (https=)
SG (1) SG191680A1 (https=)
TW (1) TWI526219B (https=)
WO (1) WO2009153992A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2311985A1 (en) 2005-07-27 2011-04-20 Oncotherapy Science, Inc. Sirna for treating esophageal cancer
PT2186889E (pt) 2007-08-20 2015-06-17 Oncotherapy Science Inc Péptido cdca1 e agente farmacêutico que o compreende
TWI526219B (zh) 2008-06-19 2016-03-21 腫瘤療法 科學股份有限公司 Ｃｄｃａ１抗原決定位胜肽及含此胜肽的疫苗
GB201004575D0 (en) * 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers
GB201004551D0 (en) 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
CN104080797A (zh) * 2011-11-11 2014-10-01 弗雷德哈钦森癌症研究中心 针对癌症的靶向细胞周期蛋白a1的t细胞免疫疗法
US20150359864A1 (en) 2012-03-09 2015-12-17 Oncotherapy Science, Inc. Pharmaceutical composition containing peptides
EP2872532A4 (en) * 2012-07-10 2016-04-13 Oncotherapy Science Inc CDCA1-EPITOPPEPTIDES FOR TH1 CELLS AND VACCINES THEREWITH
ES3009756T3 (en) 2013-08-05 2025-03-31 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumors, such as lung cancer including nsclc
TWI636065B (zh) * 2013-08-05 2018-09-21 伊瑪提克斯生物科技有限公司 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物
JP6700512B2 (ja) * 2014-08-04 2020-05-27 オンコセラピー・サイエンス株式会社 Ｃｄｃａ１由来ペプチドおよびそれを含むワクチン
JP6781508B2 (ja) * 2014-11-18 2020-11-04 塩野義製薬株式会社 安定化されたペプチド組成物
US12473336B2 (en) 2018-02-21 2025-11-18 Board Of Regents, The University Of Texas System Methods for activation and expansion of natural killer cells and uses thereof
TW202023581A (zh) * 2018-08-02 2020-07-01 日商腫瘤療法 科學股份有限公司 來自cdca1的胜肽及含有此的疫苗

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004080148A2 (en) 2002-10-02 2004-09-23 Nuvelo, Inc. Novel nucleic acids and polypeptides

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997005900A1 (en) 1995-08-03 1997-02-20 Rijksuniversiteit Te Leiden Cell derived antigen presenting vesicles
WO1998053071A1 (en) 1997-05-23 1998-11-26 Biogen, Inc. Modulators of tissue regeneration
US6800744B1 (en) 1997-07-02 2004-10-05 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics
FR2766205B1 (fr) 1997-07-16 2002-08-30 Inst Nat Sante Rech Med Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede
JP4413429B2 (ja) 1998-06-25 2010-02-10 株式会社グリーンペプタイド サイクロフィリンｂ由来の腫瘍抗原ペプチド
US7157091B1 (en) * 1999-06-18 2007-01-02 Ludwig Institute For Cancer Research MAGE-A1 peptides presented by HLA class II molecules
JP2004500029A (ja) 1999-06-30 2004-01-08 コリクサ　コーポレイション 肺癌の治療および診断のための組成物および方法
US20020172952A1 (en) 1999-06-30 2002-11-21 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US20030170255A1 (en) * 1999-06-30 2003-09-11 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US20030211510A1 (en) 1999-06-30 2003-11-13 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US6858204B2 (en) 1999-06-30 2005-02-22 Corxia Corporation Compositions and methods for the therapy and diagnosis of lung cancer
CA2384713A1 (en) 1999-09-29 2001-04-05 Human Genome Sciences, Inc. Colon and colon cancer associated polynucleotides and polypeptides
US6432966B2 (en) 1999-10-29 2002-08-13 Smithkline Beecham Corporation Antiviral combinations
US7026443B1 (en) * 1999-12-10 2006-04-11 Epimmune Inc. Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
WO2002004514A2 (en) 2000-07-11 2002-01-17 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US7214786B2 (en) 2000-12-14 2007-05-08 Kovalic David K Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement
US6867283B2 (en) 2001-05-16 2005-03-15 Technion Research & Development Foundation Ltd. Peptides capable of binding to MHC molecules, cells presenting such peptides, and pharmaceutical compositions comprising such peptides and/or cells
WO2003025010A2 (en) 2001-09-17 2003-03-27 Eirx Therapeutics Limited Human delta-n p73 molecules and uses thereof
US7892559B2 (en) 2002-01-30 2011-02-22 Survac Aps Survivin-derived peptides and use thereof
AU2003250831A1 (en) 2002-06-12 2003-12-31 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Use of hec1 antagonists in the treatment of proliferative disorders and cancer
DE60327786D1 (de) 2002-09-12 2009-07-09 Oncotherapy Science Inc Kdr-peptide und diese enthaltende impfstoffe
US20060024692A1 (en) 2002-09-30 2006-02-02 Oncotherapy Science, Inc. Method for diagnosing non-small cell lung cancers
TW200413725A (en) 2002-09-30 2004-08-01 Oncotherapy Science Inc Method for diagnosing non-small cell lung cancers
CA2500982A1 (en) 2002-09-30 2004-04-15 Oncotherapy Science, Inc. Method for diagnosing testicular seminomas
AU2003300680A1 (en) 2002-12-10 2004-07-09 Centre National De La Recherche Scientifique Cnrs Thap proteins as nuclear receptors for chemokines and roles in transcriptional regulation, cell proliferation and cell differentiation
WO2005029067A2 (en) 2003-09-24 2005-03-31 Oncotherapy Science, Inc. Method of diagnosing breast cancer
EP2336778A1 (en) 2004-03-24 2011-06-22 Oncotherapy Science, Inc. Compositions and methods for treating lung cancer
CN101175862A (zh) 2005-02-10 2008-05-07 肿瘤疗法科学股份有限公司 诊断膀胱癌的方法
EP2311985A1 (en) 2005-07-27 2011-04-20 Oncotherapy Science, Inc. Sirna for treating esophageal cancer
EP2295570A1 (en) 2005-07-27 2011-03-16 Oncotherapy Science, Inc. Method of diagnosing small cell lung cancer
EP1915622A2 (en) 2005-07-29 2008-04-30 Oncotherapy Science, Inc. Screening and therapeutic method for nsclc targeting cdca1-kntc2 complex
US7776341B2 (en) 2006-08-10 2010-08-17 Colorado State University Research Foundation Biomarkers of tuberculosis that distinguish disease categories: use as serodiagnostic antigens
PT2186889E (pt) 2007-08-20 2015-06-17 Oncotherapy Science Inc Péptido cdca1 e agente farmacêutico que o compreende
CN101827936B (zh) 2007-08-20 2014-12-10 肿瘤疗法科学股份有限公司 Cdh3肽以及含有cdh3肽的药剂
TWI526219B (zh) 2008-06-19 2016-03-21 腫瘤療法 科學股份有限公司 Ｃｄｃａ１抗原決定位胜肽及含此胜肽的疫苗
WO2011030329A1 (en) 2009-09-10 2011-03-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Method of treating tumors
EP2872532A4 (en) * 2012-07-10 2016-04-13 Oncotherapy Science Inc CDCA1-EPITOPPEPTIDES FOR TH1 CELLS AND VACCINES THEREWITH

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004080148A2 (en) 2002-10-02 2004-09-23 Nuvelo, Inc. Novel nucleic acids and polypeptides

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Harao Michiko, Kumamoto 대학교 박사학위논문 (2008. 3.).*
Kubo RT. et al, J Immunol 152:pp.3913-3924 (1994. 1.28.).*

Also Published As

Publication number Publication date
SG191680A1 (en) 2013-07-31
US9387238B2 (en) 2016-07-12
EP2303912B1 (en) 2018-01-03
WO2009153992A1 (en) 2009-12-23
IL209967A (en) 2015-09-24
CA2728268A1 (en) 2009-12-23
AU2009261382A1 (en) 2009-12-23
TW201000120A (en) 2010-01-01
CN102119171A (zh) 2011-07-06
BRPI0914782B1 (pt) 2021-08-31
ES2658842T3 (es) 2018-03-12
EP2303912A4 (en) 2012-08-29
US10711047B2 (en) 2020-07-14
MX2010014044A (es) 2011-03-03
CA2728268C (en) 2017-11-07
CN102119171B (zh) 2014-08-06
KR20160119264A (ko) 2016-10-12
IL209967A0 (en) 2011-02-28
US20110189214A1 (en) 2011-08-04
TWI526219B (zh) 2016-03-21
EP2303912A1 (en) 2011-04-06
JP2011524737A (ja) 2011-09-08
RU2502740C2 (ru) 2013-12-27
DK2303912T3 (en) 2018-03-12
KR20110031314A (ko) 2011-03-25
BRPI0914782A2 (pt) 2016-07-26
US20160272692A1 (en) 2016-09-22
RU2011101709A (ru) 2012-07-27
JP5640262B2 (ja) 2014-12-17
AU2009261382B2 (en) 2013-08-15

Similar Documents

Publication Publication Date Title
KR101705011B1 (ko) Ｃｄｃａ１ 에피토프 펩티드 및 이를 포함하는 백신
WO2010021111A1 (en) Inhbb epitope peptides and vaccines containing the same
EP2508601B1 (en) Tem8 peptides and vaccines comprising the same
KR101713581B1 (ko) Ｈｉｇ２ 및 ｕｒｌｃ１０ 에피토프 펩티드 및 이를 포함하는 백신
WO2009150835A1 (en) Iqgap3 epitope peptides and vaccines containing the same
KR101705514B1 (ko) Ｍｅｌｋ 에피토프 펩티드 및 이를 포함하는 백신
WO2009150822A1 (en) Mybl2 epitope peptides and vaccines containing the same
KR101705102B1 (ko) Ｗｄｒｐｕｈ 에피토프 펩티드 및 이를 포함하는 백신
HK1155757A (en) Cdca1 epitope peptides and vaccines containing the same
HK1155757B (en) Cdca1 epitope peptides and vaccines containing the same
HK1156341B (en) Melk epitope peptides and vaccines containing the same

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20110111

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20140610

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20160219

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20160829

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20160219

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

A107 Divisional application of patent
AMND Amendment
J201 Request for trial against refusal decision
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20160929

PJ0201 Trial against decision of rejection

Patent event date: 20160929

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20160829

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20161121

Appeal identifier: 2016101005676

Request date: 20160929

PB0901 Examination by re-examination before a trial

Comment text: Amendment to Specification, etc.

Patent event date: 20160929

Patent event code: PB09011R02I

Comment text: Request for Trial against Decision on Refusal

Patent event date: 20160929

Patent event code: PB09011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20160414

Patent event code: PB09011R02I

Comment text: Amendment to Specification, etc.

Patent event date: 20140610

Patent event code: PB09011R02I

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

Patent event date: 20161121

Comment text: Decision to Grant Registration

Patent event code: PB07012S01D

Patent event date: 20161101

Comment text: Transfer of Trial File for Re-examination before a Trial

Patent event code: PB07011S01I

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20170203

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20170206

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20200128

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20200128

Start annual number: 4

End annual number: 4

FPAY Annual fee payment

Payment date: 20210122

Year of fee payment: 5

PR1001 Payment of annual fee

Payment date: 20210122

Start annual number: 5

End annual number: 5

FPAY Annual fee payment

Payment date: 20220121

Year of fee payment: 6

PR1001 Payment of annual fee

Payment date: 20220121

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20250124

Start annual number: 9

End annual number: 9